The therapeutics pipeline of chronic kidney disease has
been increasing on account of rising prevalence of diabetes and high blood
pressure in patients. The diabetes and blood pressure are the main causes of
chronic kidney disease, which is also related to cardiovascular disease. Due to
altered lifestyle, the chances of incidence of high blood pressure and diabetes
is on a rise. Currently, the prevalence of chronic kidney disease is around 14%
in Australia, as studied by Oxford Academic Journal of Nephrology Dialysis
Transplantation. According to, National Institute of Diabetes and Digestive and
Kidney Disease, the number of kidney failure cases among the Americans stood at
more than 661,000, out of which 468,000 patients are undergoing dialysis and
193,000 patients are living with functional kidney transplant. The increasing
awareness of healthcare issues also contributes towards the of development of
therapeutics pipeline for chronic kidney disease.
Explore Report at: https://www.psmarketresearch.com/market-analysis/chronic-kidney-disease-therapeutics-pipeline-analysis
Chronic kidney disease is the condition that can lead
to the damage of the kidneys. Some of the main symptoms of chronic kidney
disease are, weight loss, insomnia, tiredness, blood in urine, feeling sick,
muscle cramps shortness of breath.
Many companies are conducting clinical trials for the development
of therapeutics for chronic kidney disease. Astellas Pharma, Inc., is in the
process of introducing a drug by the name ASP1517, which is in Phase III stage
of its clinical development. ASP1517 is an orally administered small molecule
which is used for the treatment of anaemia associated with chronic kidney
disease. AstraZeneca Plc is also introducing a drug named, Dapagliflozin, which
is currently in its Phase III stage of clnical development. Dapagliflozin is a sodium-glucose
cotransporter II inhibitor.
Request for Table
of Content at: https://www.psmarketresearch.com/market-analysis/chronic-kidney-disease-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of chronic
kidney disease therapeutics include Astellas Pharma Inc., AstraZeneca Plc, Proteon
Therapeutics, Inc., RegenMed (Cayman) Ltd, Gilead Sciences, Inc.,
GlaxoSmithKline Plc, Relypsa, Inc., Chugai Pharmaceutical, Inc., Kissei
Pharmaceutical Co., Ltd, Boryung Pharmaceutical Co., Ltd.
No comments:
Post a Comment